Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions.

Osteolytic bone disease is one of the most prominent features of multiple myeloma (MM) and is present in up to 80% of patients at diagnosis.[1][1] Bone destruction leads to skeletal-related events (i.e. vertebral and other pathological fractures) and/or spinal cord compression. MM is mainly due to